Why the Proteomics (ASX:PIQ) share price is flying 5%

The Proteomics (ASX: PIQ) share price was off to a good start today before falling flat on news it has achieved ISO certification.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After flying 5% higher this morning, it was downhill all the way for the Proteomics International Laboratories Ltd (ASX: PIQ) share price today.

At the market close today, shares in the medical technology company were right back where they started, trading at $1.18. By comparison, the S&P/ASX All Ordinaries Index (ASX: XAO) is 0.02% higher.

Today's price movement comes as the company announced one of its products received ISO certification.

asx share price fall represented by lady in striped tshirt making sad face against orange background

Image source: Getty Images

ISO Certification

In today's release, Proteomics International advised it has received ISO 13485 certification. ISO certification is an independent process that gives assurance a product or service "meets specific requirements".

The company said achieving certification would aid it in commercial discussions going forward with global diagnostic companies. It also believes the certification will "widen" the market for its PromarkerD test and make it easier to achieve regulatory approval around the world.

The PromarkerD test is used for the early detection of chronic kidney disease (CKD) in patients with type-2 diabetes. According to Proteomics, clinical studies showed 86% of patients with type-2 diabetes went on to develop CKD within 4 years.

PromarkerD tests are manufactured in Australia under licence. The company is anticipating demand for the product to boom worldwide. Recognising this, Proteomics says it is in discussions with several manufacturers in the northern hemisphere "with the objective of streamlining the future production". 

Proteomics managing director Dr Richard Lipscombe welcomed the progress, saying:

The ISO 13485 manufacturing standard provides the foundation to regulatory requirements for medical diagnostics and has been adopted by markets including the European Union, Australia, Japan, Canada and, most recently, the United States.

Proteomics share price snapshot

The Proteomics share price has increased 280% over the past 12 months and is up 51% year-to-date. At the same time, it has fallen 13% since achieving its all-time high on Monday.

Proteomics International has a market capitalisation of $129.7 million.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Woman with long hair smiles for the camera.
Healthcare Shares

Why I'd buy CSL shares while sentiment is weak

The market no longer treats this ASX healthcare giant as flawless, and that may make the investment case more interesting.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Is this exciting healthcare stock a buy, hold or sell after rocketing 16% yesterday?

Can this soaring stock keep rising?

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Broker Notes

Down 28% in a year, should I buy the dip on Resmed shares right now?

A leading analyst provides his outlook for the beaten-down ResMed share price.

Read more »

A businessman points to an arrow going up on a graph, indicating a share price rise for an ASX company.
Broker Notes

Up 1,277% in a year, why 4DMedical shares are tipped for more outsized gains

A leading analyst forecasts more outperformance from 4DMedical’s rocketing shares. But why?

Read more »

A person bounces another up high from a seesaw as the one in the air looks through a telescope into the future.
Healthcare Shares

Has the CSL share price finally bottomed out?

Is this beaten-down ASX healthcare giant finally turning a corner?

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Why everyone selling Cochlear shares right now could regret it in 3 years

Cochlear shares are down 65%. Here's why investors selling up right now could look back and wish they'd done the…

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Healthcare Shares

Here's what brokers tip for CSL shares over the next 12 months

The beaten-down biotech company's shares are still falling.

Read more »

three excited doctors with hands in the air
Healthcare Shares

Pro Medicus announces $16m US contract renewal

Pro Medicus secures a major US contract renewal, strengthening its US footprint and underlining continued client retention.

Read more »